1700054M17Rik Inhibitors consist of compounds that can indirectly modulate the activity of the protein encoded by the gene 1700054M17Rik. Given the speculative nature of the protein's function, these inhibitors target various signaling pathways and cellular processes potentially associated with 1700054M17Rik. The inhibitors operate through diverse mechanisms, such as kinase inhibition, proteasome inhibition, and modulation of gene expression, reflecting the complexity of cellular signaling.
Development of this class of inhibitors necessitates a multifaceted approach involving biochemistry, cell biology, and pharmacology. Understanding the protein's role within the cell, its interactions with other proteins, and its involvement in specific pathways is crucial for identifying potential targets for inhibition. The design and synthesis of these inhibitors are based on an intricate knowledge of the target pathways, employing advanced techniques like computational modeling and high-throughput screening. Experimental validation, including cell-based assays and in vitro studies, is essential to establish their efficacy and specificity.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor, which has shown to inhibit kinases in pathways involving 1700054M17Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, which has shown to affect PI3K/Akt signaling pathways linked with 1700054M17Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, which has shown to impact cell growth and proliferation pathways involving 1700054M17Rik. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
An HDAC inhibitor, which has shown to affect gene expression processes related to 1700054M17Rik's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An ERK pathway inhibitor, which has shown to influence pathways where 1700054M17Rik is active. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor, which has shown to disrupt signaling pathways involving 1700054M17Rik. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor, which has shown to influence protein degradation pathways related to 1700054M17Rik. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
A calcium channel blocker, which has shown to affect calcium signaling pathways involving 1700054M17Rik. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
An HDAC inhibitor, which has shown to alter chromatin structure and gene expression related to 1700054M17Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor, which has shown to impact signaling pathways involving 1700054M17Rik. | ||||||